Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EQ | Director Stock Option (right to buy) | Award | +40K | 40K | Feb 14, 2025 | Common Stock | 40K | $0.79 | Direct | F1, F2 | |||
transaction | EQ | Director Stock Option (right to buy) | Disposed to Issuer | -40K | -100% | 0 | Feb 14, 2025 | Common Stock | 40K | $3.59 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The option vests in 36 equal monthly installments following the grant date of March 1, 2022. |
F2 | On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. |